Zymeworks Inc
NASDAQ:ZYME
Zymeworks Inc
Free Cash Flow
Zymeworks Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zymeworks Inc
NASDAQ:ZYME
|
Free Cash Flow
-$113.1m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$17.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$9.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$10.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
-$1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
12%
|
CAGR 10-Years
30%
|
|
Zymeworks Inc
Glance View
Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.
See Also
What is Zymeworks Inc's Free Cash Flow?
Free Cash Flow
-113.1m
USD
Based on the financial report for Dec 31, 2024, Zymeworks Inc's Free Cash Flow amounts to -113.1m USD.
What is Zymeworks Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-3%
Over the last year, the Free Cash Flow growth was 8%. The average annual Free Cash Flow growth rates for Zymeworks Inc have been 18% over the past three years , -3% over the past five years .
You don't have any saved screeners yet